Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-08T07:53:26.640Z Has data issue: false hasContentIssue false
  • English
  • Français

No medication without representation? Generalizing from antidepressant clinical efficacy trials to clinical practice

A commentary on ‘The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice’ by van der Lem et al. (2010)

Published online by Cambridge University Press:  25 March 2011

I. M. Anderson
I. M. Anderson*
Affiliation:
Neuroscience and Psychiatry Unit, School of Community Based Medicine, Faculty of Medical and Human Sciences, University of Manchester and Manchester Academic Health Science Centre, Manchester, UK
*
*Address for correspondence: Dr I. M. Anderson, Neuroscience and Psychiatry Unit, School of Community Based Medicine, Faculty of Medical and Human Sciences, University of Manchester and Manchester Academic Health Science Centre, Stopford Building, Oxford Road, Manchester M13 9PT, UK. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antidepressantsgeneralizabilityoutcomepersonalized medicinerandomized clinical trials
Type
Commentary
Information
Psychological Medicine , Volume 41 , Issue 7 , July 2011 , pp. 1349 - 1351
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderson, IM, Ferrier, IN, Baldwin, RC, Cowen, PJ, Howard, L, Lewis, G, Matthews, K, McAllister-Williams, RH, Peveler, RC, Scott, J, Tylee, A (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 22, 343–396.CrossRefGoogle ScholarPubMed
Angst, J, Scheidegger, P, Stabl, M (1993). Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale. Clinical Neuropharmacology 16 (Suppl. 2), S55–S62.Google ScholarPubMed
Kim, JM, Kim, SW, Stewart, R, Kim, SY, Yoon, JS, Jung, SW, Lee, MS, Yim, HW, Jun, TY (2011). Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Human Psychopharmacology. Published online: 23 February 2011. doi:10.1002/hup.1168.CrossRefGoogle Scholar
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 5, e45.CrossRefGoogle ScholarPubMed
Moncrieff, J (2008). The creation of the concept of an antidepressant: an historical analysis. Social Science and Medicine 66, 2346–2355.CrossRefGoogle ScholarPubMed
O'Leary, D, Costello, F, Gormley, N, Webb, M (2000). Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. Journal of Affective Disorders 57, 159–171.Google ScholarPubMed
Pigott, HE, Leventhal, AM, Alter, GS, Boren, JJ (2010). Efficacy and effectiveness of antidepressants: current status of research. Psychotherapy and Psychosomatics 79, 267–279.CrossRefGoogle ScholarPubMed
Simon, GE, Perlis, RH (2010). Personalized medicine for depression: can we match patients with treatments? American Journal of Psychiatry 167, 1445–1455.CrossRefGoogle ScholarPubMed
Stewart, JW, McGrath, PJ, Quitkin, FM, Harrison, W, Markowitz, J, Wager, S, Leibowitz, MR (1989). Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Archives of General Psychiatry 46, 1080–1087.CrossRefGoogle ScholarPubMed
Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, Norquist, G, Howland, RH, Lebowitz, B, McGrath, PJ, Shores-Wilson, K, Biggs, MM, Balasubramani, GK, Fava, M (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28–40.CrossRefGoogle Scholar
van der Lem, R, van der Wee, NJA, van Veen, T, Zitman, FG (2010). The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychological Medicine. Published online: 16 November 2010. doi:10.1017/S0033291710002175.Google ScholarPubMed
Van Henricus, L, Schoevers, RA, Dekker, J (2008). Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harvard Review of Psychiatry 16, 225–234.Google ScholarPubMed
Wisniewski, SR, Rush, AJ, Nierenberg, AA, Gaynes, BN, Warden, D, Luther, JF, McGrath, PJ, Lavori, PW, Thase, ME, Fava, M, Trivedi, MH (2009). Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. American Journal of Psychiatry 166, 599–607.CrossRefGoogle Scholar
Zimmerman, M, Mattia, JI, Posternak, MA (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry 159, 469–473.CrossRefGoogle ScholarPubMed